复星医药：XH-S004片用于治疗慢性阻塞性肺疾病的临床试验获批

Core Viewpoint - Fosun Pharma's subsidiary, Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of XH-S004 tablets for the treatment of chronic obstructive pulmonary disease (COPD) [1] Group 1 - The drug XH-S004 is classified as a Class 1 chemical drug [1] - XH-S004 is also undergoing Phase I clinical trials in China for another indication, which is the treatment of non-cystic fibrosis bronchiectasis [1]